Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication
Category: Publication
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al.Molecular Therapy Oncolytics, September 2020 – Read the articlePublication
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al.BMC Vet Res., August 25 2020 – Read the articlePublication
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
AACR2020 6010 J. Foloppe et al. AACR 2020 Download the poster here Poster Presentation
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironmentAACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster here Poster Presentation